第41回（2025年）

Tomohiro Sasaki (Otsuka Pharmaceutical Co., Ltd.)
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan. J Pharmacokinet Pharmacodyn. 2025;52:10.

Akihiro Yamada (Astellas Pharma Inc.)
A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab. CPT Pharmacometrics Syst Pharmacol. 2025;14:572-582.